NDAORALCAPSULE
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
AMITIZA (lubiprostone) by Pfizer is chloride channel activators [moa]. Approved for chronic idiopathic constipation, constipation, irritable bowel syndrome with constipation. First approved in 2006.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMITIZA (lubiprostone) is an oral capsule chloride channel activator approved by the FDA in 2006 and currently marketed by Pfizer. It is indicated for chronic idiopathic constipation (CIC) in adults, opioid-induced constipation (OIC) in patients with chronic non-cancer pain, and irritable bowel syndrome with constipation (IBS-C) in women aged 18 and older. The drug works by activating intestinal chloride channels to increase fluid secretion and promote bowel motility, addressing multiple constipation-related conditions across different patient populations.
$0.0BPart D
1.5 years to LOEMechanism of Action
Chloride Channel Activators
Pharmacologic Class:
Chloride Channel Activator
Indications (3)
Worked on AMITIZA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.